Active material: Tobramycin
When ATH: J01GB01
CCF: Antibiotics aminoglycoside
When CSF: 06.05.01
Manufacturer: TEVA Pharmaceutical Industries Ltd. (Israel)
Solution for in / and the / m clear, nearly colourless.
| 1 ml | |
| tobramycin (in sulphate form) | 40 mg |
Excipients: disodium эdetat, sodium bisulfite, sulfuric acid, water d / and.
1 мл – ампулы (5) – блистеры (2) – пачки картонные.
Solution for in / and the / m clear, nearly colourless.
| 1 ml | 1 amp. | |
| tobramycin (in sulphate form) | 40 mg | 80 mg |
Excipients: disodium эdetat, sodium bisulfite, sulfuric acid, water d / and.
2 мл – ампулы (5) – блистеры (2) – пачки картонные.
Antibiotics group aminoglikozidov broad-spectrum. It has bactericidal activity, disrupting protein synthesis and permeability zitoplazmaticescoy membranes of bacteria.
Vsokoakteven against Pseudomonas aeruginosa.
Tobramycin active against Gram negative bacteria: Escherichia coli, Proteus spp. (indole-positive and indole-negative strains), Klebsiella spp., Serratia spp., Providencia spp., Enterobacter spp., Shigella spp., Salmonella spp., Citrobacter spp., Haemophilus influenzae; Gram-positive bacteria: Staphylococcus spp. (incl. strains, penicillinase).
Maloakteven against Streptococcus spp. (incl. Enterococcus spp.).
–
For systemic use: severe infectious and inflammatory diseases, caused by susceptible to tobramicinu agents (sepsis, meningitis, peritonitis, endokardit, respiratory tract infections, infections of skin and soft tissue, urinary tract infection, bone infection).
For topical application,: eye infection (in a combination therapy).
Individual, depending on the evidence, severity of the disease, the patient's age.
Enter / m, / drip. Applied externally and locally in the relevant dosage forms.
From the central and peripheral nervous system: Valium actions, headache, slackness, disorientation, violation of neuromuscular transmission.
From the digestive system: nausea, vomiting, increased liver transaminases and bilirubin in the blood.
From the hematopoietic system: anemia, granulocytopenia, thrombocytopenia.
Local reactions: pain at the injection site.
Metabolism: hypocalcemia, giponatriemiya, kaliopenia, gipomagniemiya.
Other: possible nephrotoxicity, allergic reactions.
Hypersensitivity to tobramicinu or other aminoglycosides.
The application of tobramycin may, When the intended benefits to the mother outweighs the treatment the risk of side effects in the foetus.
System application of tobramycin may, When the presumed benefit of treatment outweighs the risk of side effects in the following cases: in patients with impaired renal function, hearing, in myasthenia and Parkinson's.
The combined application of tobramycin with furosemidom and etakrinova acid may increase ototoksicski; other aminoglycosides, polypeptide antibiotics, некоторыми цефалоспоринами – возможно усиление нефротоксического действия тобрамицина; with miorelaxanthami (tubocurarine, etc.) – возможно усиление их мышечно-расслабляющего действия.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More